Xiaosong Luan

Novartis (Switzerland)

Papers

1

Total Citations

47

H-Index

1

About

Xiaosong Luan has made pioneering contributions to the field of biopharmaceutical formulation development, with a particular focus on antibody therapeutics. His most cited work, "Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL)" (2009), has garnered 47 citations, establishing him as an early innovator in the integration of automation and high-throughput technologies for biologics development. Luan's research centers on the intersection of robotic systems and laboratory automation, where he has developed methodologies that significantly accelerate the formulation screening and optimization process for monoclonal antibodies. His work addresses critical challenges in protein stability and formulation design, enabling more efficient and reliable development of therapeutic antibodies. By pioneering the use of robotic platforms and HTL approaches, Luan has helped transform traditional, labor-intensive formulation development into a streamlined, data-driven process. His contributions have practical implications for reducing development timelines and improving the success rates of antibody-based therapeutics, making his research highly relevant to both academic researchers and industry practitioners working in biopharmaceutical development and process optimization.

Research Focus

Key Achievements

1
H-Index
1
Papers
47
Total Citations
47
Avg Citations/Paper
🏆 Most Cited Paper
Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL)
47 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Novartis (Switzerland)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago